TY - JOUR
T1 - Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine
T2 - Effect of prior monovalent inactivated vaccine
AU - Gaglani, Manjusha
AU - Spencer, Sarah
AU - Ball, Sarah
AU - Song, Juhee
AU - Naleway, Allison
AU - Henkle, Emily
AU - Bozeman, Sam
AU - Reynolds, Sue
AU - Sessions, Wendy
AU - Hancock, Kathy
AU - Thompson, Mark
N1 - Funding Information:
Financial support. This work was supported by the CDC (contract 200-2010-F-33396 to Abt Associates Inc). This research was supported in part by an appointment to the Research Participation Program at the CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC.
PY - 2014/6/1
Y1 - 2014/6/1
N2 - Background. Few data are available on the immunogenicity of repeated annual doses of influenza A(H1N1)pdm09-containing vaccines.Methods. We enrolled healthcare personnel (HCP) in direct patient care during the autumn of 2010 at 2 centers with voluntary immunization. We verified the receipt of A(H1N1)pdm09-containing monovalent inactivated influenza vaccine (MIIV) and 2010-2011 trivalent inactivated vaccine (TIV). We performed hemagglutination inhibition antibody (HI) assays on preseason, post-TIV, and end-of-season serum samples. We compared the proportion of HCPs with HI titer ≥40 against A(H1N1)pdm09 per receipt of prior-season MIIV, current-season TIV, both, or neither. Results. At preseason (n = 1417), HI ≥ 40 was significantly higher among those who received MIIV (34%) vs those who did not (14%) (adjusted relative risk [ARR], 3.26; 95% confidence interval [CI], 2.72-3.81). At post-TIV (n = 865), HI ≥ 40 was lower among HCP who received MIIV and TIV (66%) than among those receiving only TIV (85%) (ARR, 0.93 [95% CI,. 84-.997]). At end-of-season (n = 1254), HI ≥ 40 was 40% among those who received both MIIV and TIV and 67% among those receiving only TIV (ARR, 0.76 [95% CI,. 65-.88]), 52% among those who received MIIV only, and 12% among those receiving neither.Conclusions. HCP immunization programs should consider effects of host immune response and vaccine antigenic distance on immunogenicity of repeated annual doses of influenza vaccines.
AB - Background. Few data are available on the immunogenicity of repeated annual doses of influenza A(H1N1)pdm09-containing vaccines.Methods. We enrolled healthcare personnel (HCP) in direct patient care during the autumn of 2010 at 2 centers with voluntary immunization. We verified the receipt of A(H1N1)pdm09-containing monovalent inactivated influenza vaccine (MIIV) and 2010-2011 trivalent inactivated vaccine (TIV). We performed hemagglutination inhibition antibody (HI) assays on preseason, post-TIV, and end-of-season serum samples. We compared the proportion of HCPs with HI titer ≥40 against A(H1N1)pdm09 per receipt of prior-season MIIV, current-season TIV, both, or neither. Results. At preseason (n = 1417), HI ≥ 40 was significantly higher among those who received MIIV (34%) vs those who did not (14%) (adjusted relative risk [ARR], 3.26; 95% confidence interval [CI], 2.72-3.81). At post-TIV (n = 865), HI ≥ 40 was lower among HCP who received MIIV and TIV (66%) than among those receiving only TIV (85%) (ARR, 0.93 [95% CI,. 84-.997]). At end-of-season (n = 1254), HI ≥ 40 was 40% among those who received both MIIV and TIV and 67% among those receiving only TIV (ARR, 0.76 [95% CI,. 65-.88]), 52% among those who received MIIV only, and 12% among those receiving neither.Conclusions. HCP immunization programs should consider effects of host immune response and vaccine antigenic distance on immunogenicity of repeated annual doses of influenza vaccines.
KW - 2009 influenza pandemic H1N1
KW - healthcare workers
KW - hemagglutination inhibition antibody
KW - influenza vaccine
KW - influenza vaccine immunogenicity or response
UR - http://www.scopus.com/inward/record.url?scp=84900534803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84900534803&partnerID=8YFLogxK
U2 - 10.1093/infdis/jit825
DO - 10.1093/infdis/jit825
M3 - Article
C2 - 24363436
AN - SCOPUS:84900534803
SN - 0022-1899
VL - 209
SP - 1705
EP - 1714
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 11
ER -